E-DRUG: Rethinking R&D for Pharmaceutical Products After the Novel Coronavirus
COVID-19 Shock
-----------------------------------------------------------------------------------
POLICY BRIEF 75, APRIL 2020
Rethinking R&D for Pharmaceutical Products After the Novel Coronavirus
COVID-19 Shock
By Dr. German Velasquez
The unprecedented global health crisis caused by the coronavirus COVID-19
pandemic, during the first quarter of 2020, brings back with particular
urgency the discussion about the research and development (R&D) model for
pharmaceuticals and other health technologies.
The COVID-19 crisis shows that there is an urgent need to re-design the global public health governance for health R&D. The adoption of a binding instrument 'as
allowed by Article 19 of the WHO Constitution' on this matter was proposed
many years ago. This brief argues that it is time to revive and materialize
this initiative.
Download the Policy Brief below:
Rethinking R&D for Pharmaceutical Products After the Novel Coronavirus
COVID-19 Shock
<https://www.southcentre.int/wp-content/uploads/2020/04/PB75_Rethinking-RD-for-Pharmaceutical-Products-After-the-Novel-Coronavirus-COVID-19-Shock_EN.pdf>
Dr. German Velasquez
http://www.southcentre.int
Special Adviser, Policy and Health
17-19 Chemin du Champ d'Anier
1211 Geneva 19
SWITZERLAND
gvelasquez.gva@gmail.com